THE CAPITAL PCI AF Study: The Safety and Efficacy of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention
Latest Information Update: 18 Jan 2023
At a glance
- Drugs Rivaroxaban (Primary) ; Ticagrelor (Primary)
- Indications Embolism; Myocardial infarction; Stroke; Thrombosis
- Focus Adverse reactions
- Acronyms CAPITAL PCI AF
- 12 Jan 2023 Planned End Date changed from 15 Dec 2022 to 15 Dec 2023.
- 12 Jan 2023 Planned primary completion date changed from 1 Nov 2022 to 1 Nov 2023.
- 06 Jun 2022 Planned End Date changed from 15 Dec 2021 to 15 Dec 2022.